Collegium Pharmaceutical Company Profile (NASDAQ:COLL)

About Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical logoCollegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:COLL
  • CUSIP: N/A
  • Web:
  • Market Cap: $347.1 million
  • Outstanding Shares: 29,566,000
Average Prices:
  • 50 Day Moving Avg: $10.88
  • 200 Day Moving Avg: $10.88
  • 52 Week Range: $9.27 - $18.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.24
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.44 million
  • Price / Sales: 46.65
  • Book Value: $3.23 per share
  • Price / Book: 3.63
  • EBITDA: ($97,950,000.00)
  • Net Margins: -1,319.39%
  • Return on Equity: -93.73%
  • Return on Assets: -74.81%
  • Current Ratio: 4.22%
  • Quick Ratio: 4.17%
  • Average Volume: 572,400 shs.
  • Beta: -0.11
  • Short Ratio: 20.34

Frequently Asked Questions for Collegium Pharmaceutical (NASDAQ:COLL)

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.09. The business had revenue of $3.56 million for the quarter, compared to analysts' expectations of $4.07 million. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. View Collegium Pharmaceutical's Earnings History.

When will Collegium Pharmaceutical make its next earnings announcement?

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Collegium Pharmaceutical.

Where is Collegium Pharmaceutical's stock going? Where will Collegium Pharmaceutical's stock price be in 2017?

5 brokers have issued 1 year target prices for Collegium Pharmaceutical's stock. Their predictions range from $14.00 to $25.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $20.00 in the next twelve months. View Analyst Ratings for Collegium Pharmaceutical.

Who are some of Collegium Pharmaceutical's key competitors?

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the folowing people:

  • Michael Thomas Heffernan, Chairman of the Board, President, Chief Executive Officer
  • Paul Brannelly CPA, Chief Financial Officer, Executive Vice President
  • Joseph J. Ciaffoni, Chief Operating Officer, Executive Vice President
  • Douglas R. Carlson, Vice President - Corporate Development
  • Alison B Fleming, Vice President of Product Development
  • Ernest A. Kopecky Ph.D., Vice President - Clinical Development and Head of Neuroscience
  • Kevin OKeeffe, Vice President - Market Access and Trade
  • Steven Passik Ph.D., Vice President - Scientific Affairs, Education and Policy
  • Said Saim Ph.D., Vice President of Pharmaceutical Development
  • John Weet Ph.D., Vice President - Regulatory Affairs and Quality Assurance

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

How do I buy Collegium Pharmaceutical stock?

Shares of Collegium Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Collegium Pharmaceutical's stock price today?

One share of Collegium Pharmaceutical stock can currently be purchased for approximately $11.74.

MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  110 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Collegium Pharmaceutical (NASDAQ:COLL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.00 (70.36% upside)
Consensus Price Target History for Collegium Pharmaceutical (NASDAQ:COLL)
Price Target History for Collegium Pharmaceutical (NASDAQ:COLL)
Analysts' Ratings History for Collegium Pharmaceutical (NASDAQ:COLL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Needham & Company LLCReiterated RatingBuy$25.00N/AView Rating Details
10/6/2017Jefferies Group LLCReiterated RatingBuy$15.00N/AView Rating Details
9/11/2017HC WainwrightInitiated CoverageBuy -> Buy$21.00HighView Rating Details
9/8/2017Piper Jaffray CompaniesReiterated RatingBuy$14.00LowView Rating Details
6/12/2017Janney Montgomery ScottReiterated RatingBuy$25.00MediumView Rating Details
9/13/2016GabelliInitiated CoverageBuy$25.00N/AView Rating Details
2/19/2016William BlairInitiated CoverageOutperform$35.00N/AView Rating Details
(Data available from 10/23/2015 forward)


Earnings History for Collegium Pharmaceutical (NASDAQ:COLL)
Earnings by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Earnings History by Quarter for Collegium Pharmaceutical (NASDAQ COLL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.75)N/AView Earnings Details
8/9/2017Q2 2017($0.81)($0.72)$4.07 million$3.56 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.98)($0.79)$3.55 million$2.17 millionViewN/AView Earnings Details
3/9/2017Q4 2016($1.07)($1.02)$1.79 million$1.30 millionViewListenView Earnings Details
11/10/2016Q3 2016($1.09)($1.13)$1.00 million$0.41 millionViewListenView Earnings Details
8/10/2016Q2($0.76)($1.05)$0.16 millionViewListenView Earnings Details
5/10/2016Q1($0.60)($0.68)ViewListenView Earnings Details
3/15/2016Q415($0.45)($0.46)ViewListenView Earnings Details
11/12/2015Q315($0.30)($0.46)ViewListenView Earnings Details
8/12/2015Q215($0.26)($0.45)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Collegium Pharmaceutical (NASDAQ:COLL)
2017 EPS Consensus Estimate: ($3.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.89)($0.89)($0.89)
Q2 20172($0.81)($0.76)($0.79)
Q3 20172($0.81)($0.67)($0.74)
Q4 20172($1.00)($0.61)($0.81)
(Data provided by Zacks Investment Research)


Dividend History for Collegium Pharmaceutical (NASDAQ:COLL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Collegium Pharmaceutical (NASDAQ:COLL)
Insider Ownership Percentage: 25.76%
Institutional Ownership Percentage: 83.04%
Insider Trades by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Insider Trades by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Paul BrannellyInsiderBuy10,000$9.18$91,800.00View SEC Filing  
8/12/2016John A FallonDirectorBuy2,375$10.59$25,151.25View SEC Filing  
5/12/2015John Gordon FreundDirectorBuy150,000$12.00$1,800,000.00View SEC Filing  
5/12/2015Longitude Capital Partners, LlMajor ShareholderBuy200,000$12.00$2,400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Collegium Pharmaceutical (NASDAQ:COLL)
Latest Headlines for Collegium Pharmaceutical (NASDAQ:COLL)
Loading headlines, please wait.



Collegium Pharmaceutical (COLL) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.